Dan Rogy - CeriBell Senior Operations
| CBLL Stock | 20.48 0.26 1.29% |
Executive
Dan Rogy is Senior Operations of CeriBell
| Address | 360 North Pastoria Avenue, Sunnyvale, CA, United States, 94085 |
| Phone | 800 436 0826 |
| Web | https://www.ceribell.com |
CeriBell Management Efficiency
The company has return on total asset (ROA) of (0.2874) % which means that it has lost $0.2874 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5978) %, meaning that it created substantial loss on money invested by shareholders. CeriBell's management efficiency ratios could be used to measure how well CeriBell manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.17. The value of Return On Capital Employed is expected to slide to -0.18. At this time, CeriBell's Debt To Assets are quite stable compared to the past year. Asset Turnover is expected to rise to 0.50 this year, although the value of Total Assets will most likely fall to about 136 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Collin McQuiddy | Enhabit | 49 | |
| Sean Scanlan | Treace Medical Concepts | 44 | |
| Scot JD | Treace Medical Concepts | 51 | |
| Katherine Atkinson | QuantumSi | N/A | |
| Guy Guglielmino | Treace Medical Concepts | N/A | |
| Wouter Vlaanderen | Varex Imaging Corp | N/A | |
| Adam Taich | Standard Biotools | 48 | |
| Patrick McIlvenny | Autolus Therapeutics | 47 | |
| Jeffrey Black | Standard Biotools | 55 | |
| Grace Johnston | QuantumSi | 41 | |
| John Graziano | Standard Biotools | N/A | |
| Matthew Martinez | Varex Imaging Corp | 45 | |
| Gaetano Guglielmino | Treace Medical Concepts | 56 | |
| Veronica Hersberger | Autolus Therapeutics | N/A | |
| Joel Batts | Orthopediatrics Corp | N/A | |
| Robert Okunski | Enhabit | N/A | |
| Nathan Minnich | Treace Medical Concepts | N/A | |
| Victor Ku | Butterfly Network | N/A | |
| Vesna Cizej | Autolus Therapeutics | N/A | |
| Elizabeth Jensen | Standard Biotools | 52 | |
| Jeremy Davis | Standard Biotools | N/A | |
Management Performance
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.29 |
CeriBell Leadership Team
Elected by the shareholders, the CeriBell's board of directors comprises two types of representatives: CeriBell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CeriBell. The board's role is to monitor CeriBell's management team and ensure that shareholders' interests are well served. CeriBell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CeriBell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sean Manni, Chief Officer | ||
| Kristie Rodenbush, Chief Officer | ||
| Joshua Copp, Chief Officer | ||
| David Foehr, Senior Finance | ||
| MBA JD, General Counsel | ||
| Josef MD, Chief CoFounder | ||
| Scott Blumberg, Chief Officer | ||
| Baharan Kamousi, Senior Science | ||
| Dan Rogy, Senior Operations | ||
| Joseph Manni, Chief Officer | ||
| Kim McKeon, VP Culture | ||
| Brian Price, Senior Marketing | ||
| Xingjuan Chao, President CoFounder | ||
| Raymond Woo, Chief Officer |
CeriBell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CeriBell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (0.63) % | ||||
| Operating Margin | (0.65) % | ||||
| Current Valuation | 610.67 M | ||||
| Shares Outstanding | 37.1 M | ||||
| Shares Owned By Insiders | 10.51 % | ||||
| Shares Owned By Institutions | 82.09 % | ||||
| Number Of Shares Shorted | 1.6 M | ||||
| Price To Book | 4.66 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in CeriBell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy CeriBell Stock please use our How to buy in CeriBell Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CeriBell. Projected growth potential of CeriBell fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive CeriBell assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (3.67) | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets | Return On Equity |
The market value of CeriBell is measured differently than its book value, which is the value of CeriBell that is recorded on the company's balance sheet. Investors also form their own opinion of CeriBell's value that differs from its market value or its book value, called intrinsic value, which is CeriBell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CeriBell's market value can be influenced by many factors that don't directly affect CeriBell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between CeriBell's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CeriBell should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, CeriBell's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.